Literature DB >> 19211827

Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis.

Bianca M Arendt1, Saira S Mohammed, Elaheh Aghdassi, Nita R Prayitno, David W L Ma, Augustin Nguyen, Maha Guindi, Morris Sherman, E Jenny Heathcote, Johane P Allard.   

Abstract

Hepatic fatty acid (FA) composition may influence steatosis development in patients with chronic hepatitis C (CHC). In a cross-sectional study, we compared the hepatic FA profile in hepatitis C patients with (n = 9) and without (n = 33) steatosis (> or =5% of hepatocytes involved). FA composition of hepatic and RBC total lipids was measured by gas chromatography. Lipid peroxidation and antioxidants in liver and plasma, blood biochemistry, and nutritional status were also assessed. Patients with steatosis had more fibrosis, higher necroinflammatory activity of their hepatitis C infection, were more often infected with genotype 3, and had lower serum cholesterol. Monounsaturated FA in the liver were higher and trans FA were lower in patients with steatosis. Lower stearic acid and higher oleic acid in hepatic total lipids suggested higher Delta9-desaturase activity. alpha-Linolenic acid in the liver was higher and the ratios of long-chain PUFA:essential FA precursors were lower for (n-3) and (n-6) PUFA. Plasma vitamin C was lower in steatosis, but RBC FA composition and other parameters did not differ. We conclude that hepatic FA composition is altered in patients with hepatitis C and steatosis, probably due to modulation of enzymatic elongation and desaturation. Oxidative stress or nutritional status does not seem to play a predominant role for development of steatosis in CHC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211827     DOI: 10.3945/jn.108.101782

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  8 in total

Review 1.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

2.  Inhibition of MEK/ERK1/2 Signaling Affects the Fatty Acid Composition of HepG2 Human Hepatic Cell Line.

Authors:  Bahman Yousefi; Masoud Darabi; Behzad Baradaran; Mahmoud Shekari Khaniani; Mohammad Rahbani; Maryam Darabi; Shabnam Fayezi; Amir Mehdizadeh; Negar Saliani; Maghsod Shaaker
Journal:  Bioimpacts       Date:  2012-06-27

3.  Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Thierry Umbdenstock; Cédric Vinson; Murielle Combettes; Brant de Fanti; Elizabeth Harley; Marjorie Sadlo; Anne-Laure Lefèvre; Olivier Broux; Michel Wierzbicki; Jean-Marie Fourquez; Françoise Perron-Sierra; András Kotschy; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Suppressive Role of PPARγ-Regulated Endothelial Nitric Oxide Synthase in Adipocyte Lipolysis.

Authors:  Yoko Yamada; Masato Eto; Yuki Ito; Satoru Mochizuki; Bo-Kyung Son; Sumito Ogawa; Katsuya Iijima; Masao Kaneki; Koichi Kozaki; Kenji Toba; Masahiro Akishita; Yasuyoshi Ouchi
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients.

Authors:  Sadia Qamar Arain; Farah Naz Talpur; Naseem Aslam Channa; Muhammad Shahbaz Ali; Hassan Imran Afridi
Journal:  Lipids Health Dis       Date:  2017-03-01       Impact factor: 3.876

6.  Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Authors:  Kelli A Lytle; Carmen P Wong; Donald B Jump
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

7.  A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.

Authors:  Sadia Qamar Arain; Farah Naz Talpur; Naseem Aslam Channa
Journal:  Lipids Health Dis       Date:  2015-09-24       Impact factor: 3.876

8.  Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.

Authors:  D W L Ma; B M Arendt; L M Hillyer; S K Fung; I McGilvray; M Guindi; J P Allard
Journal:  Nutr Diabetes       Date:  2016-07-18       Impact factor: 5.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.